NHS Lothian Shared Care Agreements

Access NHS Lothian Shared Care Agreements, policies and procedures

The NHS Lothian Policy and Procedures for the Shared Care of Medicines is available from the NHS Lothian Medicines Governance Policies page. Template documents relating to local shared care arrangements are available on NHS Lothian Policy Online.

For the purposes of this policy a medicine is considered to be eligible for a shared care arrangement if it can be initiated in secondary care and then prescribed by a GP in primary care and meets the following criteria:

  • prescribed for a potentially serious condition
  • complex (intended use likely to be outwith the clinical experience of a GP)
  • relatively high adverse effects profile
  • may require specific monitoring and dose titration
  • new, or rarely prescribed

All approved NHS Lothian Shared Care Agreements (SCAs) will be listed on this page. These are locally approved documents which provide additional guidance to GPs for complex treatments, routinely used in a specialist setting and approved as appropriate for use in primary care.

Medicine Indication
alirocumab Hypercholesterolaemia and elevated (atherosclerotic) cardiovascular risk
atomoxetine Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older
azathioprine For the treatment of adults with inflammatory rheumatic, bowel and skin diseases
aztreonam lysine (Cayston) Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older
bempedoic acid Primary hypercholesterolaemia or mixed dyslipidaemia, where maximally-tolerated lipid-lowering therapy has failed to achieve target LDL cholesterol
buprenorphine Maintenance treatment of opioid dependence
ciclosporin (Capimune) Inflammatory rheumatic and skin conditions
ciclosporin (Neoral) Solid organ transplant in adult patients
cinacalcet Secondary hyperparathyroidism in patients with end stage renal disease on dialysis
colistimethate sodium Chronic pulmonary Pseudomonas aeruginosa infection in children and adults with cystic fibrosis and adults with non-cystic fibrosis bronchiectasis
dexamfetamine and lisdexamfetamine Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older
dornase alfa Management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted and over 5 years of age to improve pulmonary function
Erythropoiesis Stimulating Agents (ESAs) Chronic renal failure
evolocumab Hypercholesterolaemia and elevated (atherosclerotic) cardiovascular risk
Feminising endocrine treatment (Estradiol and GnRHa) Gender dysphoria/incongruence after assessment at the GIC for over 18 year olds
guanfacine Attention deficit hyperactivity disorder (ADHD) in children aged 6 to 18 years
hydroxycarbamide Myeloproliferative neoplasms including essential thrombocythaemia, polycythaemia vera, myelofibrosis and chronic myelomonocytic leukaemia
hydroxychloroquine Inflammatory rheumatic diseases
ketamine Complex pain in palliative care patients
lanreotide long acting and octreotide long acting (somatostatin analogues) Acromegaly
lanreotide and octreotide (somatostatin analogues) Neuroendocrine tumours
leflunomide Inflammatory rheumatic diseases
liraglutide Weight loss
Masculinising endocrine treatment (Testosterone) Gender dysphoria/incongruence after assessment at the GIC for over 18 year olds
mercaptopurine Inflammatory bowel disease (ulcerative colitis and Crohn’s disease)
methotrexate (oral and subcutaneous) Adults with inflammatory rheumatic, bowel and skin conditions
methotrexate (oral and subcutaneous) Paediatric inflammatory
rheumatic and bowel conditions
methylphenidate Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 and older
mycophenolate mofetil (MMF) and mycophenolic acid (Myfortic) Solid organ transplant adult patients
mycophenolate mofetil (MMF) For non-transplant indications
mycophenolic acid Uveitis
penicillamine Inflammatory rheumatic diseases
riluzole Amyotrophic lateral sclerosis (ALS) motor neurone disease
roxadustat Management of symptomatic anaemia in patients with chronic renal failure
somatropin (recombinant human growth hormone) Adult hypopituitarism
somatropin (recombinant human growth hormone) Growth failure/disturbance in children
sulfasalazine Inflammatory rheumatic diseases
Test SCA Test SCA Lothian
tacrolimus (Adoport, Prograf, Advagraf) Solid organ transplants in adult patients
tacrolimus Uveitis
tenofovir disoproxil fumarate Chronic hepatitis B infection in adults
tobramycin Chronic pulmonary Pseudomonas Aeruginosa infection in children and adults with cystic fibrosis
valganciclovir Prevention of CMV infection in solid organ transplant